KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

被引：74
|
作者：
Brahmer, J. R. [1 ]
Rodriguez-Abreu, D. [2 ]
Robinson, A. G. [3 ,4 ]
Hui, R. [3 ,4 ]
Csoszi, T. [5 ]
Fulop, A. [6 ]
Gottfried, M. [7 ]
Peled, N. [8 ]
Tafreshi, A. [9 ,10 ]
Cuffe, S. [11 ,12 ]
O'Brien, M. [13 ]
Rao, S. [14 ]
Hotta, K. [15 ]
Leal, T. A. [16 ]
Riess, J. W. [17 ]
Jensen, E. [18 ]
Zhao, B. [18 ]
Pietanza, M. C. [18 ]
Reck, M. [19 ]
机构：
[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Oncol, Baltimore, MD USA
[2] Hosp Univ Insular Gran Canaria, Med Oncol, Las Palmas Gran Canaria, Spain
[3] Westmead Hosp, Med Oncol, Sydney, NSW, Australia
[4] Univ Sydney, Sydney, NSW, Australia
[5] Jasz Nagykun Szolnok Cty Hosp, Oncol, Szolnok, Hungary
[6] Orszagos Koranyi Pulmonol Intezet, Med Oncol, Budapest, Hungary
[7] Meir Med Ctr, Med Oncol, Kefar Sava, Israel
[8] Soroka Univ Med Ctr, Ctr Canc, Beer Sheva, Israel
[9] Wollongong Private Hosp, Med Oncol, Wollongong, NSW, Australia
[10] Univ Wollongong, Wollongong, NSW, Australia
[11] St James Hosp, Med Oncol, Dublin, Ireland
[12] Canc Trials Ireland, Dublin, Ireland
[13] Royal Marsden Hosp, Med Oncol, Sutton, Surrey, England
[14] MedStar Franklin Sq Hosp, Med Oncol, Baltimore, MD USA
[15] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan
[16] Univ Wisconsin, Carbone Canc Ctr, Div Hematol & Oncol, Madison, WI USA
[17] UC Davis Comprehens Canc Ctr, Div Hematol Oncol, Sacramento, CA USA
[18] Merck & Co Inc, Oncol, Kenilworth, NJ USA
[19] German Ctr Lung Res, Airway Res Ctr North, Lungen Clin, Grosshansdorf, Germany
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA51
引用
收藏
页码：S1181 / S1182
页数：2
相关论文
共 50 条
  • [41] Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%
    Jimenez Alguilar, E.
    Gainor, J.
    Kravets, S.
    Khosrowjerdi, S.
    Lydon, C.
    Adeni, A.
    Subegdjo, S.
    Rizvi, H.
    Hellmann, M.
    Awad, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S367 - S368
  • [42] Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
    Cortellini, Alessio
    Brunetti, Leonardo
    Di Fazio, Giuseppina Rita
    Garbo, Edoardo
    Pinato, David J.
    Naidoo, Jarushka
    Katz, Artur
    Loza, Monica
    Neal, Joel W.
    Genova, Carlo
    Gettinger, Scott
    Kim, So Yeon
    Jayakrishnan, Ritujith
    El Zarif, Talal
    Russano, Marco
    Pecci, Federica
    Di Federico, Alessandro
    Awad, Mark
    Alessi, Joao, V
    Montrone, Michele
    Owen, Dwight Hall
    Signorelli, Diego
    Fidler, Mary Jo
    Li, Mingjia
    Camerini, Andrea
    De Giglio, Andrea
    Young, Lauren
    Vincenzi, Bruno
    Metro, Giulio
    Passiglia, Francesco
    Yendamuri, Sai
    Guida, Annalisa
    Ghidini, Michele
    Awosika, Nichola O.
    Napolitano, Andrea
    Fulgenzi, Claudia A. M.
    Grisanti, Salvatore
    Grossi, Francesco
    D'Incecco, Armida
    Josephides, Eleni
    Van Hemelrijck, Mieke
    Russo, Alessandro
    Gelibter, Alain
    Spinelli, Gianpaolo
    Verrico, Monica
    Tomasik, Bartlomiej
    Giusti, Raffaele
    Newsom-Davis, Thomas
    Bria, Emilio
    Sebastian, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [43] Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
    Akinboro, Oladimeji
    Vallejo, Jonathon Joseph
    Nakajima, Erica C.
    Ren, Yi
    Mishra-Kalyani, Pallavi Shruti
    Larkins, Erin A.
    Vellanki, Paz J.
    Drezner, Nicole Lauren
    Mathieu, Luckson Noe
    Donoghue, Martha Boeri
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Sacituzumab govitecan (SG) plus pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02
    Patel, Jyoti D.
    Cho, Byoung Chul
    Cobo, Manuel
    Cabanillas, Roxana Reyes
    Vicente, David
    Pradera, Jose Fuentes
    Garon, Edward B.
    Mok, Tony S. K.
    Cappuzzo, Federico
    Neal, Joel W.
    Mekan, Sabeen Fatima
    Safavi, Farnoush
    Fernando, Nelumka
    Chisamore, Michael Jon
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
    Dudnik, Elizabeth
    Moskovitz, Mor
    Rottenberg, Yakir
    Lobachov, Anastasiya
    Mandelboim, Rinat
    Shochat, Tzippy
    Urban, Damien
    Wollner, Mira
    Nechushtan, Hovav
    Rotem, Ofer
    Zer, Alona
    Daher, Sameh
    Bar, Jair
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [46] Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC
    Reinmuth, Niels
    Spigel, David
    De Marinis, Filippo
    Giaccone, Giuseppe
    Verynenegre, Alain
    Barrios, Carlos Henrique
    Morise, Masahiro
    Felip, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozgueroglur, Mustafa
    Mocci, Simonetta
    Mccleland, Mark
    Enquist, Ida
    Kotnatsubara, Kim
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    Jassem, Jacek
    Herbst, Roy S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 233
  • [47] First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%
    Descourt, Renaud
    Chouaid, Christos
    Perol, Maurice
    Besse, Benjamin
    Greillier, Laurent
    Bylicki, Olivier
    Ricordel, Charles
    Guisier, Florian
    Gervais, Radj
    Schott, Roland
    Auliac, Jean-Bernard
    Robinet, Gilles
    Decroisette, Chantal
    FUTURE ONCOLOGY, 2021, 17 (23) : 3007 - 3016
  • [48] Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up
    Abreu, D. Rodriguez
    Reck, M.
    Sendur, N.
    Park, K.
    Lee, D. H.
    Cicin, I.
    Yumuk, P. F.
    Orlandi, F. J.
    Leal, T. A.
    Soparattanapaisarn, N.
    Langleben, A.
    Califano, R.
    Medgyasszay, B.
    Hsia, T-C.
    Otterson, G. A.
    Woods, T.
    Jensen, E.
    Samkari, A.
    Boyer, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S30 - S31
  • [49] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib (ola) vs pembro plus chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
    Saji, S.
    Cussac, A. Llombart
    Andre, F.
    Robson, M. E.
    Harbeck, N.
    Schmid, P.
    Cescon, D. W.
    Ahn, J. S.
    Nanda, R.
    Fan, L.
    Mejia, J. A.
    Karantza, V.
    Bardia, A.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1268 - S1268
  • [50] Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
    Pons-Tostivint, E.
    Hulo, P.
    Guardiolle, V.
    Bodot, L.
    Rabeau, A.
    Porte, M.
    Hiret, S.
    Demontrond, P.
    Curcio, H.
    Boudoussier, A.
    Veillon, R.
    Mayenga, M.
    Dumenil, C.
    Chatellier, T.
    Gourraud, P. A.
    Mazieres, J.
    Bennouna, J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) : 1881 - 1890
12345